LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article ; Online: Antibody and complement in transplant vasculopathy.

Wehner, Jennifer / Morrell, Craig N / Reynolds, Taylor / Rodriguez, E Rene / Baldwin, William M

2007 Volume 100, Issue 2, Page(s) 191–203

Abstract: ... in the pathogenesis of transplant vasculopathy. Recent findings indicate that antibodies and complement produced ... to coronary vasculopathy in cardiac transplants. Antibodies and complement can have independent effects ... Transplant vasculopathy has also been referred to as accelerated graft arteriosclerosis because it has ...

Abstract	Advances in immunosuppression have decreased the incidence of acute rejection, but the development of vasculopathy in the coronary arteries of transplants continues to limit the survival of cardiac allografts. Transplant vasculopathy has also been referred to as accelerated graft arteriosclerosis because it has features of arteriosclerosis, but it is limited to the graft and develops over a period of months to years. Although the pathological features of transplant vasculopathy are well defined, the causative mechanisms are not completely understood. This review focuses on the mechanisms by which antibody and complement can cause or contribute to coronary vasculopathy in cardiac transplants. Antibodies and complement can have independent effects, but the combination of antibodies and complement with inflammatory cells has greater pathogenic potential for the endothelial and smooth muscle cells of the coronary arteries. For example, stimulation through receptors for IgG or complement split products can activate macrophages, but stimulation through combinations of these receptors generates synergistic results. Together, antibodies and complement efficiently integrate the activation of endothelial cells, platelets, and macrophages, which are 3 of the primary components in the pathogenesis of transplant vasculopathy. Recent findings indicate that antibodies and complement produced within the transplant may contribute to vascular pathology in some transplants. Acute rejection caused by antibodies and complement has been treated by combinations of plasmapheresis, intravenous gamma-globulin and monoclonal antibodies to CD20 on B lymphocytes. The effect of these treatment modalities on the development of coronary vasculopathy is unknown.
MeSH term(s)	Animals ; Antibodies/physiology ; Complement System Proteins/physiology ; Coronary Vessels/immunology ; Coronary Vessels/pathology ; Coronary Vessels/transplantation ; Graft Rejection/immunology ; Graft Rejection/pathology ; Heart Transplantation/immunology ; Humans
Chemical Substances	Antibodies ; Complement System Proteins (9007-36-7)
Language	English
Publishing date	2007-02-02
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	80100-8
ISSN	1524-4571 ; 0009-7330 ; 0931-6876
ISSN (online)	1524-4571
ISSN	0009-7330 ; 0931-6876
DOI	10.1161/01.RES.0000255032.33661.88
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui IV Zs.70: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Ui IV Zs.60: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Intermediate-term outcomes of complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients.

Coutance, Guillaume / Kobashigawa, Jon A / Kransdorf, Evan / Loupy, Alexandre / Desiré, Eva / Kittleson, Michelle / Patel, Jignesh K

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

2023 Volume 42, Issue 10, Page(s) 1464–1468

Abstract: ... transplant. The primary end-point was antibody-mediated rejection ≥ pAMR2 and/or left ventricular dysfunction ... favorable 1-year outcomes of complement inhibition at transplant in highly sensitized recipients. We now ... The median follow-up was 4.8 years. Beyond the first year post-transplant, there were no episodes of pAMR2 or ...

Abstract	Allosensitization represents a major barrier to heart transplantation. We previously reported favorable 1-year outcomes of complement inhibition at transplant in highly sensitized recipients. We now report a longer follow-up. In this single-arm trial (NCT02013037), 20 patients with panel reactive antibodies ≥70% and preformed donor-specific antibodies received eculizumab during the first 2 months post-transplant. The primary end-point was antibody-mediated rejection ≥ pAMR2 and/or left ventricular dysfunction. The median follow-up was 4.8 years. Beyond the first year post-transplant, there were no episodes of pAMR2 or greater and no Left Ventricular (LV) dysfunction. There were 3 deaths, 1 episode of pAMR1, and 1 patient with minimal de novo cardiac allograft vasculopathy. Compared to a matched control group, we observed a nonstatistically significant benefit of eculizumab with a lower incidence of the primary end-point or death (primary end-point: hazard ratio = 0.50, 95% confidence interval = 0.15-1.67, and p = 0.26; mortality: hazard ratio = 0.51, 95% confidence interval = 0.13-2.07, and p = 0.35). Our results support the utility of complement inhibition for high-immunological-risk recipients. CLINICAL TRIAL REGISTRATION: ClinincalTrials.gov, NCT02013037. https://clinicaltrials.gov/ct2/show/NCT02013037?term=eculizumab&cond=heart+transplantation&draw=2&rank=1.
MeSH term(s)	Humans ; Allografts ; Graft Rejection ; Heart Transplantation ; HLA Antigens ; Isoantibodies ; Tissue Donors
Chemical Substances	HLA Antigens ; Isoantibodies
Language	English
Publishing date	2023-05-12
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1062522-7
ISSN	1557-3117 ; 1053-2498
ISSN (online)	1557-3117
ISSN	1053-2498
DOI	10.1016/j.healun.2023.05.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2056: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The effects of donor-specific antibody characteristics on cardiac allograft vasculopathy.

Wang, Maggie / Patel, Nikhil J / Zhang, Xiaohai / Kransdorf, Evan P / Azarbal, Babak / Kittleson, Michelle M / Czer, Lawrence S C / Kobashigawa, Jon A / Patel, Jignesh K

Clinical transplantation

2021 Volume 35, Issue 12, Page(s) e14483

Abstract: Background: Cardiac allograft vasculopathy (CAV) causes late graft dysfunction and post-transplant ... dilution DSA (n = 45), complement-binding (C1q) DSA (n = 36), Class I DSA (n = 37), and Class II DSA (n ... unclear.: Method: We evaluated 526 adult heart transplant recipients at a single center between January ...

Abstract	Background: Cardiac allograft vasculopathy (CAV) causes late graft dysfunction and post-transplant mortality. Currently, the effects of different donor-specific antibodies (DSA) on the severity of CAV remain unclear. Method: We evaluated 526 adult heart transplant recipients at a single center between January 2010 and August 2015. Subjects were divided into those with DSA (n = 142) and those without DSA (n = 384, control). The DSA group was stratified into persistent DSA (n = 34), transient DSA (n = 105), 1:8 dilution DSA (n = 45), complement-binding (C1q) DSA (n = 36), Class I DSA (n = 37), and Class II DSA (n = 105). The primary outcome was the incidence of moderate-to-severe CAV (CAV 2/3) at 5-year follow-up. Results: Subjects with persistent DSA, 1:8 dilution DSA, and C1q DSA had higher incidence of CAV 2/3 compared the control group (17.6%, 13.3%, and 16.7% vs. 3.1%, respectively; P≤ .001). The incidence of CAV 2/3 between subjects with transient DSA and the control group was similar (2.8% vs. 3.1%; P = .888). Subjects with Class II DSA also had higher incidence of CAV 2/3 (7.6% vs. 3.1%; P = .039). Conclusion: DSA that are persistent, 1:8 dilution positive, C1q positive, and Class II are associated with more severe grades of CAV. These DSA characteristics may prognosticate disease and warrant consideration for treatment.
MeSH term(s)	Adult ; Allografts ; Graft Rejection/etiology ; HLA Antigens ; Heart Transplantation/adverse effects ; Humans ; Retrospective Studies
Chemical Substances	HLA Antigens
Language	English
Publishing date	2021-10-28
Publishing country	Denmark
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639001-8
ISSN	1399-0012 ; 0902-0063
ISSN (online)	1399-0012
ISSN	0902-0063
DOI	10.1111/ctr.14483
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: When to intervene for donor-specific antibody after heart transplantation.

Njue, Faith / Chih, Sharon

Current opinion in organ transplantation

2019 Volume 24, Issue 3, Page(s) 271–278

Abstract: ... associated with rejection, cardiac allograft vasculopathy, allograft failure, and mortality. Advances ... those in whom DSA arise de novo posttransplant, is persistent, high titer, or complement activating. The impact ... represent a complex area in heart transplantation with nonstandardized practice and paucity of clinical data ...

Abstract	Purpose of review: Posttransplant donor-specific human leukocyte antigen (HLA) antibodies (DSA) represent a complex area in heart transplantation with nonstandardized practice and paucity of clinical data to guide optimal management. Recent findings: De novo DSA after heart transplantation is common and associated with rejection, cardiac allograft vasculopathy, allograft failure, and mortality. Advances in methods for HLA antibody detection have enabled identification of DSA with high precision and sensitivity. The detection of HLA antibodies must, however, be interpreted within appropriate laboratory and clinical contexts; it remains unclear which DSA are associated with greatest clinical risk. Increased antibody and clinical surveillance as well as optimization of maintenance immunosuppression are required for all patients with DSA. Antibody-directed therapies are reserved for patients with allograft dysfunction or rejection. Treatment of DSA may also be considered in asymptomatic high-risk patients including those in whom DSA arise de novo posttransplant, is persistent, high titer, or complement activating. The impact of DSA reduction and removal on long-term clinical outcomes remains unknown. Summary: Despite improvements in DSA detection, identification, and characterization, best therapeutic strategies are unclear. Prospective multicenter studies are needed to develop effective standardized approaches for DSA management in heart transplantation.
MeSH term(s)	Female ; Graft Rejection/immunology ; Heart Transplantation/adverse effects ; Heart Transplantation/methods ; Humans ; Isoantibodies/immunology ; Male ; Prospective Studies
Chemical Substances	Isoantibodies
Language	English
Publishing date	2019-07-08
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1390429-2
ISSN	1531-7013 ; 1087-2418
ISSN (online)	1531-7013
ISSN	1087-2418
DOI	10.1097/MOT.0000000000000634
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5609: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Antibody-mediated rejection in heart transplantation: new developments and old uncertainties.

Manfredini, Valentina / Leone, Ornella / Agostini, Valentina / Potena, Luciano

Current opinion in organ transplantation

2017 Volume 22, Issue 3, Page(s) 207–214

Abstract: ... of the mechanisms behind AMR and of its relationship with cellular rejection and chronic vasculopathy. In-depth ... for clinical management of heart transplant because of its diagnostic complexity and poor evidences supporting ... of the immune-pathological graft abnormalities, and by new molecular approaches allowing a better understanding ...

Abstract	Purpose of review: Antibody-mediated rejection (AMR) currently represents one of the main problems for clinical management of heart transplant because of its diagnostic complexity and poor evidences supporting treatments. Recent findings: Disorder-based diagnosis is a cornerstone in defining AMR. The limitations of the current classification have been partially overcome by novel studies improving the description of the immune-pathological graft abnormalities, and by new molecular approaches allowing a better understanding of the mechanisms behind AMR and of its relationship with cellular rejection and chronic vasculopathy. In-depth characterization of donor-specific antibodies showed to provide additional prognostic information and guide for treatment. Clinical relevance of AMR is bound to appropriate detection of graft dysfunction. In addition to traditional longitudinal evaluation by echocardiogram, cardiac magnetic resonance and detection of cell-free DNA may represent novel sensitive markers for graft injury that could prompt treatment before dysfunction becomes clinically manifest. Summary: Despite improvements in the diagnostic process, therapeutic strategies made little progress in addition to the consolidation of practices supported by limited evidences. Novel complement inhibitors appear promising in changing this scenario. Nevertheless, collaborative multicenter studies are needed to develop standardized approaches tailored to the highly variable clinical and laboratory features of AMR.
Language	English
Publishing date	2017-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	1390429-2
ISSN	1531-7013 ; 1087-2418
ISSN (online)	1531-7013
ISSN	1087-2418
DOI	10.1097/MOT.0000000000000407
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5609: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation.

Su, Jennifer A / Baxter-Lowe, Lee Ann / Kantor, Paul F / Szmuszkovicz, Jacqueline R / Menteer, JonDavid

Current opinion in organ transplantation

2019 Volume 24, Issue 3, Page(s) 245–251

Abstract: ... vasculopathy, and mortality. Importantly, different DSA vary in clinical significance. DSA capable ... of activating the complement cascade portend a higher risk of developing AMR. human leukocyte antigen class I and class II ... of graft loss and mortality. When comparing preexisting DSA with formation of de-novo DSA, de-novo DSA are ...

Abstract	Purpose of review: Outcomes after cardiac transplantation have improved over past decades, but long-term graft survival remains limited in part because of uncertainty regarding clinical implications of donor-specific antibodies (DSAs). The purpose of this review is to consolidate recent advances in knowledge on the topic of DSA and their potential to impact long-term prognosis after heart transplantation. Recent findings: The presence of persistent DSA increases the risk of poor outcome after heart transplantation, including development of antibody-mediated rejection (AMR), graft failure, cardiac allograft vasculopathy, and mortality. Importantly, different DSA vary in clinical significance. DSA capable of activating the complement cascade portend a higher risk of developing AMR. human leukocyte antigen class I and class II antigens are expressed differently within the heart, and so, clinical manifestations of class I and class II DSA vary accordingly. Further, compared with class I, class II DSA carry an increased risk of graft loss and mortality. When comparing preexisting DSA with formation of de-novo DSA, de-novo DSA are associated with worse outcome. Summary: DSAs are generally associated worse long-term prognosis after heart transplantation but vary in their clinical significance. Recognition of specific risk profiles is essential for guiding posttransplant antibody management.
MeSH term(s)	Antibodies/immunology ; Antibody Specificity ; Graft Rejection/immunology ; HLA Antigens/immunology ; Heart Transplantation ; Humans ; Prognosis ; Tissue Donors ; Transplantation Immunology
Chemical Substances	Antibodies ; HLA Antigens
Language	English
Publishing date	2019-07-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1390429-2
ISSN	1531-7013 ; 1087-2418
ISSN (online)	1531-7013
ISSN	1087-2418
DOI	10.1097/MOT.0000000000000636
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5609: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Label-free Identification of Antibody-mediated Rejection in Cardiac Allograft Biopsies Using Infrared Spectroscopic Imaging.

Uraizee, Imran / Varma, Vishal K / Sreedhar, Hari / Gambacorta, Francesca / Nazeer, Shaiju S / Husain, Aliya / Walsh, Michael J

Transplantation

2018 Volume 103, Issue 4, Page(s) 698–704

Abstract: ... of developing chronic allograft vasculopathy. Diffuse immunohistochemical C4d staining of capillary endothelia ... understood than acute cellular rejection, is associated with worse outcomes, and portends a greater risk ... right ventricular tissue biopsies (14 positive for C4d and 16 negative for C4d) and 14 native heart biopsies were ...

Abstract	Background: Antibody-mediated rejection (AMR) in cardiac allograft recipients remains less well-understood than acute cellular rejection, is associated with worse outcomes, and portends a greater risk of developing chronic allograft vasculopathy. Diffuse immunohistochemical C4d staining of capillary endothelia in formalin-fixed, paraffin-embedded right ventricular endomyocardial biopsies is diagnostic of immunopathologic AMR but serves more as a late-stage marker. Infrared (IR) spectroscopy may be a useful tool in earlier detection of rejection. We performed mid-IR spectroscopy to identify a unique biochemical signature for AMR. Methods: A total of 30 posttransplant formalin-fixed paraffin-embedded right ventricular tissue biopsies (14 positive for C4d and 16 negative for C4d) and 14 native heart biopsies were sectioned for IR analysis. Infrared images of entire sections were acquired and regions of interest from cardiomyocytes were identified. Extracted spectra were averaged across many pixels within each region of interest. Principal component analysis coupled with linear discriminant analysis and predictive classifiers were applied to the data. Results: Comparison of averaged mid-IR spectra revealed unique features among C4d-positive, C4d-negative, and native heart biopsies. Principal component analysis coupled with linear discriminant analysis and classification models demonstrated that spectral features from the mid-IR fingerprint region of these 3 groups permitted accurate automated classification into each group. Conclusions: In cardiac allograft biopsies with immunopathologic AMR, IR spectroscopy reveals a biochemical signature unique to AMR compared with that of nonrejecting cardiac allografts and native hearts. Future study will focus on the predictive capabilities of this IR signature.
MeSH term(s)	Adult ; Aged ; Antibodies/immunology ; Biopsy ; Complement C4b/analysis ; Female ; Graft Rejection/etiology ; Heart Transplantation/adverse effects ; Humans ; Male ; Middle Aged ; Myocardium/pathology ; Peptide Fragments/analysis ; Spectrophotometry, Infrared/methods
Chemical Substances	Antibodies ; Peptide Fragments ; Complement C4b (80295-50-7) ; complement C4d (80295-52-9)
Language	English
Publishing date	2018-09-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	208424-7
ISSN	1534-6080 ; 0041-1337
ISSN (online)	1534-6080
ISSN	0041-1337
DOI	10.1097/TP.0000000000002465
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 488: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 509: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Antibody-mediated rejection: an evolving entity in heart transplantation.

Chih, Sharon / Chruscinski, Andrzej / Ross, Heather J / Tinckam, Kathryn / Butany, Jagdish / Rao, Vivek

Journal of transplantation

2012 Volume 2012, Page(s) 210210

Abstract: ... heart transplantation, posing a significant risk for allograft failure, cardiac allograft vasculopathy, and poor ... with emerging agents including proteasome and complement inhibitors showing particular promise. While there have ... through complement activation. The diagnosis of AMR has evolved from a clinical diagnosis involving allograft dysfunction and ...

Abstract	Antibody-mediated rejection (AMR) is gaining increasing recognition as a major complication after heart transplantation, posing a significant risk for allograft failure, cardiac allograft vasculopathy, and poor survival. AMR results from activation of the humoral immune arm and the production of donor-specific antibodies (DSA) that bind to the cardiac allograft causing myocardial injury predominantly through complement activation. The diagnosis of AMR has evolved from a clinical diagnosis involving allograft dysfunction and the presence of DSA to a primarily pathologic diagnosis based on histopathology and immunopathology. Treatment for AMR is multifaceted, targeting inhibition of the humoral immune system at different levels with emerging agents including proteasome and complement inhibitors showing particular promise. While there have been significant advances in our current understanding of the pathogenesis, diagnosis, and treatment of AMR, further research is required to determine optimal diagnostic tools, therapeutic agents, and timing of treatment.
Language	English
Publishing date	2012-03-26
Publishing country	United States
Document type	Journal Article
ZDB-ID	2503421-2
ISSN	2090-0015 ; 2090-0007
ISSN (online)	2090-0015
ISSN	2090-0007
DOI	10.1155/2012/210210
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft.

Fishbein, Gregory A / Fishbein, Michael C

Human immunology

2012 Volume 73, Issue 12, Page(s) 1213–1217

Abstract: ... that can result in allograft dysfunction, allograft loss, accelerated graft vasculopathy, and increased mortality ... The morphologic hallmark is microvascular injury with immunoglobulin and complement deposition in capillaries ... AMR is thought to represent antibody/complement mediated injury to the microvasculature of the graft ...

Abstract	The recognition and acceptance of the entity of antibody-mediated rejection (AMR) of solid organs has been slow to develop. Greatest acceptance and most information relates to cardiac transplantation. AMR is thought to represent antibody/complement mediated injury to the microvasculature of the graft that can result in allograft dysfunction, allograft loss, accelerated graft vasculopathy, and increased mortality. The morphologic hallmark is microvascular injury with immunoglobulin and complement deposition in capillaries, accumulation of intravascular macrophages, and in more severe cases, microvascular hemorrhage and thrombosis, with inflammation and edema of the affected organ. Understanding of the pathogenesis of AMR, criteria and methods for diagnosis, and treatment strategies are still in evolution, and will be addressed in this review.
MeSH term(s)	Antibodies/immunology ; Antibodies/metabolism ; Antibody-Dependent Cell Cytotoxicity ; Biomarkers/metabolism ; Complement C4/immunology ; Complement C4/metabolism ; Graft Rejection/diagnosis ; Graft Rejection/epidemiology ; Graft Rejection/immunology ; Graft Rejection/pathology ; HLA Antigens/immunology ; HLA Antigens/metabolism ; Heart Transplantation/immunology ; Heart Transplantation/pathology ; Humans ; Prevalence ; Risk Factors ; Transplantation, Homologous
Chemical Substances	Antibodies ; Biomarkers ; Complement C4 ; HLA Antigens
Language	English
Publishing date	2012-12
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	801524-7
ISSN	1879-1166 ; 0198-8859
ISSN (online)	1879-1166
ISSN	0198-8859
DOI	10.1016/j.humimm.2012.07.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1597: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation.

Chang, David / Kobashigawa, Jon

Current opinion in organ transplantation

2012 Volume 17, Issue 4, Page(s) 423–426

Abstract: ... rejection and cardiac allograft vasculopathy, and decreased survival. Solid-phase assays to determine antibody ... Functional antibody assessment, placement of a LVAD as bridge to cardiac transplant, and novel means ... Recent findings: Expansion of the donor pool and decreased waiting time for heart transplant may be ...

Abstract	Purpose of review: Alloantibodies to human leukocyte antigens (HLAs) in patients awaiting heart transplantation are associated with prolonged wait time to transplant, increased risk of posttransplant rejection and cardiac allograft vasculopathy, and decreased survival. Solid-phase assays to determine antibody presence have allowed for the development of a calculated panel-reactive antibody to denote unacceptable antigens. The virtual crossmatch allows for the comparison of recipient HLA antibodies to prospective donor HLA antigens to safely match a patient to an appropriate donor without a prospective crossmatch. Recent findings: Expansion of the donor pool and decreased waiting time for heart transplant may be impacted by further assessment of the functional status of alloantibodies and novel means for desensitization. Sensitized patients who receive left ventricular assist device (LVAD) as a bridge to cardiac transplant appear to have similar postoperative 1-year outcomes compared with nonsensitized patients. Summary: Antibody sensitization poses an additional hurdle to patients awaiting heart transplantation. Functional antibody assessment, placement of a LVAD as bridge to cardiac transplant, and novel means of desensitization may impact a sensitized patient's ability to safely undergo heart transplantation.
MeSH term(s)	Antibodies/immunology ; Complement C1q/analysis ; Desensitization, Immunologic/methods ; HLA Antigens/immunology ; Heart Diseases/surgery ; Heart Transplantation/immunology ; Heart-Assist Devices/adverse effects ; Histocompatibility Testing/methods ; Humans ; Isoantibodies/blood ; Isoantibodies/immunology
Chemical Substances	Antibodies ; HLA Antigens ; Isoantibodies ; Complement C1q (80295-33-6)
Language	English
Publishing date	2012-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1390429-2
ISSN	1531-7013 ; 1087-2418
ISSN (online)	1531-7013
ISSN	1087-2418
DOI	10.1097/MOT.0b013e328355f195
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5609: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito